Insider Selling: ICU Medical (NASDAQ:ICUI) Director Sells 65 Shares of Company Stock

Key Points

• Director Elisha Finney sold 65 ICU Medical shares at an average price of $179, worth $11,635, reducing her stake by 1.32%; she retained 4,871 shares.
• ICU Medical beat quarterly earnings expectations, reporting $2.44 per share versus the $2.14 consensus, while revenue rose 4.4% year over year to $556.22 million.
• Analysts’ consensus rating was Moderate Buy, with an average price target of $195.20; shares traded at $179.27 after rising on Friday.

ICU Medical, Inc. (NASDAQ:ICUI - Get Free Report) Director Elisha Finney sold 65 shares of the company's stock in a transaction that occurred on Thursday, November 12th. The stock was sold at an average price of $179.00, for a total value of $11,635.00. Following the sale, the director directly owned 4,871 shares in the company, valued at $871,909. This trade represents a 1.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

ICU Medical Price Performance

Shares of NASDAQ ICUI traded up $1.97 during midday trading on Friday, reaching $179.27. 195,454 shares of the stock traded hands, compared to its average volume of 283,069. The company's 50 day moving average is $163.46 and its 200 day moving average is $149.76. ICU Medical, Inc. has a one year low of $113.37 and a one year high of $192.85. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.37 and a quick ratio of 1.19. The stock has a market capitalization of $4.48 billion, a PE ratio of 75.01, a P/E/G ratio of 2.24 and a beta of 0.88.

ICU Medical (NASDAQ:ICUI - Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The medical instruments supplier reported $2.44 earnings per share for the quarter, topping the consensus estimate of $2.14 by $0.30. The company had revenue of $556.22 million for the quarter, compared to analysts' expectations of $552.03 million. ICU Medical had a net margin of 2.76% and a return on equity of 8.40%. ICU Medical's quarterly revenue was up 4.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.03 earnings per share. On average, equities research analysts anticipate that ICU Medical, Inc. will post 7.22 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on ICUI shares. Zacks Research cut shares of ICU Medical from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 28th. Weiss Ratings upgraded ICU Medical from a "hold (c-)" rating to a "hold (c)" rating in a research report on Thursday, October 8th. Raymond James Financial reissued a "strong-buy" rating and set a $200.00 price objective on shares of ICU Medical in a research note on Friday, August 7th. Piper Sandler upped their price objective on ICU Medical from $195.00 to $200.00 and gave the company an "overweight" rating in a research report on Friday, November 6th. Finally, KeyCorp raised their price objective on ICU Medical from $187.00 to $189.00 and gave the company an "overweight" rating in a research note on Friday, November 6th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, ICU Medical has an average rating of "Moderate Buy" and an average target price of $195.20.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ICUI. Versant Capital Management Inc grew its position in shares of ICU Medical by 26.2% in the 3rd quarter. Versant Capital Management Inc now owns 313 shares of the medical instruments supplier's stock worth $50,000 after buying an additional 65 shares during the last quarter. Bessemer Group Inc. lifted its stake in ICU Medical by 65.8% during the 3rd quarter. Bessemer Group Inc. now owns 189 shares of the medical instruments supplier's stock valued at $29,000 after acquiring an additional 75 shares during the period. Nisa Investment Advisors LLC lifted its position in ICU Medical by 1.3% during the third quarter. Nisa Investment Advisors LLC now owns 6,088 shares of the medical instruments supplier's stock valued at $977,000 after purchasing an additional 79 shares during the period. California Public Employees Retirement System boosted its stake in shares of ICU Medical by 0.3% in the first quarter. California Public Employees Retirement System now owns 30,461 shares of the medical instruments supplier's stock worth $3,934,000 after buying an additional 90 shares during the last quarter. Finally, Hantz Financial Services Inc. boosted its position in ICU Medical by 78.4% in the 3rd quarter. Hantz Financial Services Inc. now owns 239 shares of the medical instruments supplier's stock worth $38,000 after purchasing an additional 105 shares in the last quarter. Hedge funds and other institutional investors own 96.10% of the company's stock.

ICU Medical Company Profile

ICU Medical is a medical technology company that develops, manufactures and markets products used in infusion therapy, vascular access and critical care. Its offerings include infusion pumps and related sets and accessories, IV solutions, needlefree connectors, and products designed to help protect healthcare workers when handling hazardous drugs. Founded in 1984, the company expanded its product portfolio through acquisitions, including the infusion systems business of Hospira in 2017 and Smiths Medical in 2022.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.